AKR7A2 | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
fibroblast	20 studies	24% ± 9%	Explore
natural killer cell	13 studies	23% ± 8%	Explore
ciliated cell	13 studies	40% ± 16%	Explore
myofibroblast cell	9 studies	22% ± 4%	Explore
connective tissue cell	9 studies	31% ± 9%	Explore
pericyte	9 studies	22% ± 6%	Explore
plasmacytoid dendritic cell	9 studies	28% ± 9%	Explore
CD8-positive, alpha-beta T cell	8 studies	20% ± 5%	Explore
smooth muscle cell	8 studies	21% ± 3%	Explore
CD16-negative, CD56-bright natural killer cell, human	7 studies	20% ± 4%	Explore
basal cell	6 studies	31% ± 15%	Explore
B cell	6 studies	19% ± 6%	Explore
conventional dendritic cell	6 studies	32% ± 16%	Explore
epithelial cell of proximal tubule	6 studies	38% ± 9%	Explore
abnormal cell	6 studies	21% ± 4%	Explore
endothelial cell	6 studies	26% ± 11%	Explore
epithelial cell	6 studies	46% ± 16%	Explore
CD16-positive, CD56-dim natural killer cell, human	5 studies	19% ± 3%	Explore
enterocyte	5 studies	28% ± 7%	Explore
dendritic cell	5 studies	36% ± 19%	Explore
CD4-positive, alpha-beta T cell	4 studies	18% ± 1%	Explore
classical monocyte	4 studies	23% ± 6%	Explore
progenitor cell	4 studies	21% ± 6%	Explore
goblet cell	4 studies	24% ± 8%	Explore
mesothelial cell	4 studies	35% ± 18%	Explore
transit amplifying cell	4 studies	24% ± 6%	Explore
regulatory T cell	4 studies	18% ± 1%	Explore
enteroendocrine cell	4 studies	30% ± 16%	Explore
deuterosomal cell	3 studies	36% ± 1%	Explore
pancreatic A cell	3 studies	40% ± 15%	Explore
type B pancreatic cell	3 studies	39% ± 13%	Explore
effector memory CD8-positive, alpha-beta T cell	3 studies	16% ± 2%	Explore
hematopoietic precursor cell	3 studies	39% ± 14%	Explore
mature NK T cell	3 studies	19% ± 1%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	3 studies	20% ± 4%	Explore
non-classical monocyte	3 studies	30% ± 6%	Explore
kidney loop of Henle epithelial cell	3 studies	19% ± 3%	Explore
kidney distal convoluted tubule epithelial cell	3 studies	19% ± 0%	Explore
intestinal crypt stem cell	3 studies	25% ± 8%	Explore
neural crest cell	3 studies	20% ± 2%	Explore
common myeloid progenitor	3 studies	30% ± 14%	Explore
hematopoietic stem cell	3 studies	21% ± 5%	Explore
type I pneumocyte	3 studies	23% ± 4%	Explore
Mueller cell	3 studies	23% ± 6%	Explore
effector CD8-positive, alpha-beta T cell	3 studies	16% ± 1%	Explore
macrophage	3 studies	23% ± 5%	Explore
luminal hormone-sensing cell of mammary gland	3 studies	27% ± 10%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
intestine	8 studies	22% ± 11%	Explore
lung	7 studies	27% ± 10%	Explore
kidney	6 studies	20% ± 7%	Explore
peripheral blood	4 studies	24% ± 7%	Explore
pancreas	3 studies	37% ± 12%	Explore
placenta	3 studies	22% ± 3%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
esophagus	100%	1928.29	1445 / 1445	100%	67.56	183 / 183
ovary	100%	2502.57	180 / 180	100%	108.87	430 / 430
pancreas	100%	1516.88	328 / 328	100%	80.22	178 / 178
prostate	100%	1897.41	245 / 245	100%	101.66	502 / 502
stomach	100%	1875.39	359 / 359	100%	86.91	286 / 286
brain	100%	1663.28	2639 / 2642	100%	88.43	705 / 705
uterus	100%	2218.78	170 / 170	100%	98.05	458 / 459
liver	100%	1862.81	226 / 226	100%	78.35	405 / 406
skin	100%	2225.03	1808 / 1809	100%	109.72	471 / 472
thymus	100%	1773.99	653 / 653	100%	90.73	603 / 605
intestine	100%	2287.83	966 / 966	100%	93.49	525 / 527
lung	100%	1474.52	576 / 578	100%	77.30	1154 / 1155
breast	100%	2002.69	459 / 459	99%	113.36	1112 / 1118
kidney	100%	3644.78	89 / 89	99%	106.92	894 / 901
bladder	100%	1693.90	21 / 21	99%	91.52	500 / 504
adrenal gland	100%	3678.88	258 / 258	93%	54.93	215 / 230
adipose	100%	1868.18	1204 / 1204	0%	0	0 / 0
eye	0%	0	0 / 0	100%	100.10	80 / 80
lymph node	0%	0	0 / 0	100%	88.61	29 / 29
spleen	100%	1593.08	241 / 241	0%	0	0 / 0
tonsil	0%	0	0 / 0	100%	80.12	45 / 45
ureter	0%	0	0 / 0	100%	38.58	1 / 1
muscle	100%	1738.04	801 / 803	0%	0	0 / 0
blood vessel	100%	1416.52	1329 / 1335	0%	0	0 / 0
heart	99%	1325.04	849 / 861	0%	0	0 / 0
peripheral blood	89%	1031.92	830 / 929	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0

III. Associated gene sets

GO_0044597	Biological process	daunorubicin metabolic process
GO_0005975	Biological process	carbohydrate metabolic process
GO_0006081	Biological process	cellular aldehyde metabolic process
GO_0006629	Biological process	lipid metabolic process
GO_0044598	Biological process	doxorubicin metabolic process
GO_0070062	Cellular component	extracellular exosome
GO_0005829	Cellular component	cytosol
GO_0005794	Cellular component	Golgi apparatus
GO_0005737	Cellular component	cytoplasm
GO_0005739	Cellular component	mitochondrion
GO_0004033	Molecular function	aldo-keto reductase (NADPH) activity
GO_0004032	Molecular function	aldose reductase (NADPH) activity
GO_0019119	Molecular function	phenanthrene-9,10-epoxide hydrolase activity
GO_0005515	Molecular function	protein binding
GO_0009055	Molecular function	electron transfer activity

IV. Literature review

[source]

Gene name	AKR7A2
Protein name	Aflatoxin B1 aldehyde reductase member 2 (EC 1.1.1.n11) (AFB1 aldehyde reductase 1) (AFB1-AR 1) (Aldoketoreductase 7) (Succinic semialdehyde reductase) (SSA reductase) Aldo-keto reductase family 7, member A2 (Aflatoxin aldehyde reductase) (Epididymis secretory sperm binding protein Li 166mP) Aldo-keto reductase family 7 member A2
Synonyms	AFAR1 HEL-S-166mP AFAR AKR7 hCG_40469
Description	FUNCTION: Catalyzes the NADPH-dependent reduction of succinic semialdehyde to gamma-hydroxybutyrate. May have an important role in producing the neuromodulator gamma-hydroxybutyrate (GHB). Has broad substrate specificity. Has NADPH-dependent aldehyde reductase activity towards 2-carboxybenzaldehyde, 2-nitrobenzaldehyde and pyridine-2-aldehyde (in vitro). Can reduce 1,2-naphthoquinone and 9,10-phenanthrenequinone (in vitro). Can reduce the dialdehyde protein-binding form of aflatoxin B1 (AFB1) to the non-binding AFB1 dialcohol. May be involved in protection of liver against the toxic and carcinogenic effects of AFB1, a potent hepatocarcinogen. .
Accessions	H3BLU7 H7C5H7 ENST00000330072.9 ENST00000481966.1 ENST00000489286.5 O43488 V9HWA2 H7C4Q7 ENST00000235835.8

AKR7A2 report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review